Answers are grounded in this paper and cite their sources.
Introduction Megaprosthetic reconstruction (MPR) is associated with a substantially higher risk of periprosthetic joint infection (PJI) compared to primary total joint arthroplasty. However, evidence guiding the optimal duration of antibiotic prophylaxis remains limited, and institutional practices vary considerably. The purpose of this study was to evaluate the incidence of PJI, antibiotic-related complications, and surgical outcomes in patients undergoing MPR followed by a prolonged prophylactic antibiotic regimen. Materials and methods This retrospective single-centre study included patients undergoing MPR between May 2020 and November 2022 at a tertiary sarcoma referral centre. All patients received a standardised postoperative 12-week prophylactic antibiotic regimen consisting of two weeks of intravenous ampicillin/sulbactam followed by 10 weeks of oral rifampin and levofloxacin. The primary outcome was the incidence of PJI. Secondary outcomes included surgery-related complication and revision rates, antibiotic-related adverse events, and mortality. Results A total of 47 patients were included into the study, of which 83% underwent MPR for oncologic conditions. The overall PJI rate was 2.1% at a mean follow-up of 39 months. Surgery-related complications occurred in 4.3%, and the revision rate was 4.3%. No antibiotic-related adverse events were documented during inpatient treatment or follow-up. All-cause mortality was 21.3%. Conclusions In this retrospective case series, a low incidence of PJI was observed in patients undergoing MPR followed by a standardised 12-week prophylactic antibiotic regimen. Thus, these findings might support the notion that extended prophylaxis could be a safe and effective strategy in high-risk patients undergoing MPR. However, the study design, limited sample size and absence of a control group restrict the conclusions that can be drawn from these findings, and comparative prospective studies are required to determine the effectiveness of prolonged antibiotic prophylaxis following MPR.
No takes yet. Share an insight, caveat, or question.
Stauss et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: